{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:20:27Z","timestamp":1769822427441,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.trim.2022.101732","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T02:56:52Z","timestamp":1667185012000},"page":"101732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy individuals: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"75","author":[{"given":"Tahoora","family":"Mousavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monireh","family":"Golpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Alizadeh-Navaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Mardomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.trim.2022.101732_bb0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7322\/jhgd.v30.9976","article-title":"The dissemination of COVID-19: an expectant and preventive role in global health","volume":"30","author":"Pimentel","year":"2020","journal-title":"J. Human Growth Develop."},{"key":"10.1016\/j.trim.2022.101732_bb0010","unstructured":"https:\/\/covid19.WWcC-d, who.int\/ (accessed Nov 29)."},{"issue":"13","key":"10.1016\/j.trim.2022.101732_bb0015","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus\u2013infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10223","key":"10.1016\/j.trim.2022.101732_bb0020","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.trim.2022.101732_bb0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.trim.2022.101732_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/vaccines9040365","article-title":"Strategies for immunomonitoring after vaccination and during infection","volume":"9","author":"Adam","year":"2021","journal-title":"Vaccines."},{"issue":"7","key":"10.1016\/j.trim.2022.101732_bb0035","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3390\/diagnostics11071135","article-title":"Evaluation of anti-SARS-Cov-2 S-RBD Igg antibodies after COVID-19 mRNA BNT162b2 vaccine","volume":"11","author":"Lo Sasso","year":"2021","journal-title":"Diagnostics."},{"issue":"3","key":"10.1016\/j.trim.2022.101732_bb0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4155\/tde-2020-0129","article-title":"An overview of vaccine development for COVID-19","volume":"12","author":"Shahcheraghi","year":"2021","journal-title":"Therapeutic delivery"},{"issue":"6496","key":"10.1016\/j.trim.2022.101732_bb0045","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science."},{"issue":"1","key":"10.1016\/j.trim.2022.101732_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-52768-7","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.trim.2022.101732_bb0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/labmed\/lmab032","article-title":"Clinical utility of midregional proadrenomedullin in patients with COVID-19","volume":"52","author":"Lo Sasso","year":"2021","journal-title":"Lab. Med."},{"issue":"9","key":"10.1016\/j.trim.2022.101732_bb0060","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.trim.2022.101732_bb0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijtb.2020.10.012","article-title":"Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?","volume":"68","author":"Gong","year":"2021","journal-title":"Indian J. Tuberc."},{"issue":"2","key":"10.1016\/j.trim.2022.101732_bb0070","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.17744","article-title":"Cutaneous findings following COVID-19 vaccination: review of world literature and own experience","volume":"36","author":"Gambichler","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.trim.2022.101732_bb0075","series-title":"Application of Microbes in Vaccine Production. Application of Microbes in Environmental and Microbial Biotechnology","first-page":"573","author":"Bagchi","year":"2022"},{"issue":"7","key":"10.1016\/j.trim.2022.101732_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008548","article-title":"Developing a low-cost and accessible COVID-19 vaccine for global health","volume":"14","author":"Hotez","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.trim.2022.101732_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108162","article-title":"A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines","volume":"100","author":"Ghasemiyeh","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.trim.2022.101732_bb0090","series-title":"Principles in Immunology for the Design and Development of Vaccines. Vaccine Design","first-page":"27","author":"Meyer","year":"2022"},{"issue":"11","key":"10.1016\/j.trim.2022.101732_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056106","article-title":"Protocol: safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy individuals: protocol for a systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.trim.2022.101732_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-021-00878-5","article-title":"Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Chen","year":"2021","journal-title":"Infect. Dis. Poverty."},{"key":"10.1016\/j.trim.2022.101732_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112650","article-title":"Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine","volume":"147","author":"Nguyen","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.trim.2022.101732_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2","volume":"6","author":"McDonald","year":"2021","journal-title":"npj Vaccines."},{"key":"10.1016\/j.trim.2022.101732_bb0115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial","volume":"22","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.trim.2022.101732_bb0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/vaccines10010086","article-title":"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine","volume":"10","author":"Kanokudom","year":"2022","journal-title":"Vaccines."},{"issue":"1","key":"10.1016\/j.trim.2022.101732_bb0125","first-page":"e2029111-1","article-title":"Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults","volume":"18","author":"Wanlapakorn","year":"2021","journal-title":"MedRxiv."},{"issue":"12","key":"10.1016\/j.trim.2022.101732_bb0130","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1002\/jmv.27203","article-title":"Safety and effectiveness of SARS-CoV-2 vaccines: a systematic review and meta-analysis","volume":"93","author":"Ling","year":"2021","journal-title":"J. Med. Virol."},{"issue":"12","key":"10.1016\/j.trim.2022.101732_bb0135","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/pathogens10121537","article-title":"Safety and seroconversion of immunotherapies against SARS-CoV-2 infection: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Ma","year":"2021","journal-title":"Pathogens."},{"issue":"1","key":"10.1016\/j.trim.2022.101732_bb0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/07357907.2021.1992420","article-title":"Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy","volume":"40","author":"Ariamanesh","year":"2022","journal-title":"Cancer Investig."},{"issue":"10","key":"10.1016\/j.trim.2022.101732_bb0145","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.trim.2022.101732_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101226","article-title":"Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study","volume":"43","author":"Feng","year":"2022","journal-title":"eClinicalMedicine."},{"issue":"3","key":"10.1016\/j.trim.2022.101732_bb0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/vaccines9030227","article-title":"SARS-CoV-2 neutralizing antibodies: a network meta-analysis across vaccines","volume":"9","author":"Rogliani","year":"2021","journal-title":"Vaccines."},{"issue":"6","key":"10.1016\/j.trim.2022.101732_bb0160","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"12","key":"10.1016\/j.trim.2022.101732_bb0165","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"10296","key":"10.1016\/j.trim.2022.101732_bb0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.trim.2022.101732_bb0175","series-title":"Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv","author":"Bueno","year":"2021"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:03:57Z","timestamp":1760810637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422002064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":35,"alternative-id":["S0966327422002064"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101732","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy individuals: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101732"}}